Journal
EXPERIMENTAL BIOLOGY AND MEDICINE
Volume 247, Issue 15, Pages 1388-1396Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/15353702221099579
Keywords
Ivermectin; COVID-19; pandemics; SARS-CoV-2; hypoxia-inducible factor-alpha; importin; inflammation; lung
Categories
Funding
- Medical Research Council, Hamadan University of Medical Sciences, Hamadan, Iran [400798125]
Ask authors/readers for more resources
Ivermectin shows therapeutic potential for treating COVID-19 infection by inhibiting virus adhesion and replication, and clinical evidence suggests its effectiveness in all phases.
COVID-19 is a critical pandemic that affected communities around the world, and there is currently no specific drug treatment for it. The virus enters the human cells via spikes and induces cytokine production and finally arrests the cell cycle. Ivermectin shows therapeutic potential for treating COVID-19 infection based on in vitro studies. Docking studies have shown a strong affinity between Ivermectin and some virulence factors of COVID-19. Notably, clinical evidence has demonstrated that Ivermectin with usual doses is effective by both the prophylactic and therapeutic approaches in all phases of the disease. Ivermectin inhibits both the adhesion and replication of the virus. Local therapy of the lung with Ivermectin or combination therapy may get better results and decrease the dose of the drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available